Alignment Healthcare Inc
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
ALHC$7.67+5.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Activities: | ||
| Net loss | $(9,354) | $(46,575) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Loss on right of use assets | — | 143 |
| Depreciation and amortization | 7,627 | 6,029 |
| Amortization-investment discount | (370) | (1,153) |
| Amortization-debt issuance costs | 440 | 520 |
| Equity-based compensation | 17,187 | 20,854 |
| Non-cash lease expense | 395 | 472 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (60,155) | (45,322) |
| Prepaid expenses and other current assets | (43,800) | (8,886) |
| Other assets | (23) | (114) |
| Medical expenses payable | 106,946 | 71,065 |
| Accounts payable and accrued expenses | 5,208 | 48 |
| Deferred premium revenue | 157 | (59) |
| Accrued compensation | (7,577) | (2,505) |
| Lease liabilities | (65) | (755) |
| Net cash provided by (used in) operating activities | 16,616 | (6,238) |
| Investing Activities: | ||
| Purchase of investments | (17,905) | (21,564) |
| Maturities of investments | 22,695 | 75,390 |
| Acquisition of property and equipment | (8,252) | (11,121) |
| Net cash (used in) provided by investing activities | (3,462) | 42,705 |
| Financing Activities: | ||
| Payment of employment taxes related to release of restricted stock | — | (350) |
| Debt issuance costs | (26) | — |
| Proceeds from stock option exercises | 207 | — |
| Contributions from noncontrolling interest holders | — | 15 |
| Net cash provided by (used in) financing activities | 181 | (335) |
| Net increase in cash | 13,335 | 36,132 |
| Cash, cash equivalents and restricted cash at beginning of period | 434,942 | 204,954 |
| Cash, cash equivalents and restricted cash at end of period | $448,277 | $241,086 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $— | $5,175 |
| Supplemental non-cash investing and financing activities: | ||
| Acquisition of property in accounts payable | $85 | $156 |
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total above:
| March 31, 2025 | March 31, 2024 | |
|---|---|---|
| Cash and cash equivalents | $446,184 | $238,903 |
| Restricted cash in other assets | 2,093 | 2,183 |
| Total | $448,277 | $241,086 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.